Leadless & Miniaturized Pacemaker Patent Landscape
The leadless and miniaturized pacemaker patent field is heavily concentrated, with Pacesetter Inc commanding the dominant position among the top applicants and the top five filers together accounting for 78% of the hundred largest filers’ combined output. Annual filing volume has eased back from its 2020 peak, placing the field in a late-stage, past-peak lifecycle — though adjacent branches in wireless communication and power management remain comparatively sparse.
Pacesetter Inc leads a tightly consolidated field
Pacesetter Inc holds the top-ranked position by a wide margin, followed by Biotronik SE & Co KG, Medtronic Inc, Cardiac Pacemakers Inc, and MicroPort Sorin CRM (Shanghai) Co Ltd, which together form a distinct first tier well ahead of all other applicants.
The top five filers account for 78% of the hundred largest filers’ combined patent records, signaling an unusually high degree of concentration. A pronounced tier gap separates the top five from the remaining ranked applicants, whose individual record counts drop sharply below the leaders.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Pacesetter Inc | 381 | |
| 2 | BIOTRONIK SE & CO KG | 167 | |
| 3 | Medtronic Inc | 129 | |
| 4 | Cardiac Pacemakers Inc | 97 | |
| 5 | MicroPort Sorin CRM (Shanghai) Co Ltd | 56 | |
| 6 | NanoStim Inc | 29 | |
| 7 | Axonics Inc | 20 | |
| 8 | Intermedics Inc | 14 | |
| 9 | Eagle Point Medical LLC | 12 | |
| 10 | Leadway Inc | 12 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Douglas Donald D | 10 | |
| 12 | The Regents of the University of California | 8 | |
| 13 | Texas Heart Institute | 7 | |
| 14 | NEURO & CARDIAC TECHNOLOGIES LLC | 7 | |
| 15 | Korea Institute of Medical Microrobotics | 5 | |
| 16 | Osaka University | 5 | |
| 17 | JMC Corp | 5 | |
| 18 | EBR Systems Inc | 5 | |
| 19 | LG Research Partnership | 5 | |
| 20 | University Health Network | 5 |
The leaders’ entrenched positions suggest that core electrotherapy and device architecture claims are already densely filed, making differentiation through adjacent technical branches — such as wireless telemetry, antenna design, or power management — a more viable entry strategy for challengers and new entrants.
Filing counts for 2024 and 2025 are subject to publication lag and understate actual activity; no conclusions about real-time competitive momentum should be drawn from the most recent two years. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing activity peaked in 2020; electrotherapy dominates the technology mix
The annual filing trend reveals a field that surged through 2019–2020 and has since eased, while the technology composition chart shows near-total dominance of the A61N electrotherapy class with a long tail of sparser adjacent branches.
Annual filing trend
Filings climbed sharply to a peak in 2019–2020 (116 and 118 patent records respectively) before moderating in subsequent years. The 2023–2025 values reflect publication lag and should be read as a floor, not a ceiling — actual filed volume in those years is likely higher. The multi-year trajectory confirms a past-peak but still substantive field.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) overwhelmingly dominates the technology mix, reflecting the core pacing and stimulation function of the devices. A61B (Diagnosis and surgery) and A61M (Devices for body fluids — principally catheter delivery) form a secondary cluster. Branches such as H04B (Transmission), G16H (Healthcare informatics), H01Q (Antennas), and H02J (Power supply) each represent a small fraction of records, indicating that wireless communication, digital health integration, and energy harvesting remain comparatively underdeveloped areas.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Leadless pacemaker and leadless pacemaker system
A leadless pacemaker and a leadless pacemaker system are disclosed. A housing of a pacemaker body of the leadless pacemaker is designed as a curved tubular structure and can be deployed at a site with a limited space in a curved configuration, which allows the curved surface structure to fit more closely myocardial or vascular tissue around the site… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Percutaneously placed electrical gastrointestinal … | 524 |
| 2 | Implantable lead system | 472 |
| 3 | Leadless Cardiac Pacemaker with Secondary Fixation… | 459 |
| 4 | Leadless cardiac pacer | 455 |
| 5 | Leadless cardiac pacemaker system with conductive … | 358 |
| 6 | Implanted medical device telemetry using integrate… | 356 |
| 7 | Leadless magnetic cardiac pacemaker | 346 |
| 8 | Leadless cardiac pacemaker with conducted communic… | 343 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the landscape structure means for R&D investment decisions
The combination of high concentration, a past-peak lifecycle, and a thin tail of adjacent-branch filings shapes where differentiation is realistically achievable and where defensive exposure exists.
Field is in decline from a 2020 peak
The lifecycle stage is classified as Decline, with annual filing volume easing back from the 2020 peak of 118 patent records. Core electrotherapy and device architecture claims are densely filed by incumbent leaders, leaving limited room for broad foundational patents. New entrants should expect to navigate a thicket of existing claims rather than open ground in the central technology space.
Lifecycle: DeclineTop five filers hold 78% of the top-100 combined output
Pacesetter Inc, Biotronik, Medtronic, Cardiac Pacemakers Inc, and MicroPort Sorin CRM together represent 78% of the hundred largest filers’ combined patent records. This degree of concentration is characteristic of a mature medical device segment where incumbents have built broad claim portfolios. Challengers face both freedom-to-operate risk and a significant volume disadvantage in any direct technology confrontation with the tier-one filers.
High concentrationCo-filing activity is limited to NanoStim-linked inventors
The collaboration evidence shows OSTROFF ALAN and JACOBSON PETER M each co-filing with NanoStim Inc (3 and 1 joint records respectively). Co-filing activity across the broader landscape is sparse, suggesting that development in this field is predominantly conducted within individual corporate entities rather than through open consortia or academic-industry partnerships. This limits visibility into informal R&D collaboration that may be occurring outside the patent record.
Limited co-filingUS-centric filing with meaningful EPO and PCT coverage
The United States is the lead jurisdiction by a substantial margin, followed by Europe (EPO) and WIPO (PCT) filings. China shows a comparatively modest presence, though MicroPort Sorin CRM (Shanghai) Co Ltd’s appearance in the top five applicants indicates growing domestic Chinese activity. Japan, Canada, and Australia each have limited but present filings. Entrants targeting Asian markets may find more navigable freedom-to-operate conditions than in the US or European jurisdictions.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| OSTROFF ALAN | NanoStim Inc | 3 |
| Jacobson Peter M | NanoStim Inc | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Pacesetter and Biotronik lead; Medtronic shows the strongest upward momentum
The top tier is separated from challengers by a wide record-count gap. Recent filing momentum diverges notably across the leaders, with Medtronic increasing activity while Pacesetter and MicroPort Sorin CRM have both pulled back.
Pacesetter Inc
Pacesetter Inc holds 381 patent records — more than double the next-ranked applicant — concentrated in A61N 1 (Electrotherapy, 329 records), with secondary positions in A61M 25 (Catheter delivery, 83 records) and A61B 17 (Surgical methods, 80 records). This breadth across core electrotherapy and delivery-system claims reflects a comprehensive blocking position. Recent-period filings show a trend of -44% versus the prior period, consistent with a mature, consolidated portfolio entering a maintenance phase.
patent records: 381Medtronic Inc
Medtronic Inc holds 129 patent records, focused on A61N 1 (Electrotherapy, 128 records) with secondary activity in A61B 5 (Diagnosis, 21 records) and H01G 4 (Capacitors, 5 records) — the latter hinting at energy storage differentiation. Notably, Medtronic’s recent filing trend shows +88% versus its prior three-year period, the strongest upward momentum among the top four applicants and a signal of renewed or accelerated investment in this space.
patent records: 129| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Pacesetter Inc | 82 | ▼ -44% |
| Biotronik SE & Co KG | 63 | ▬ -5% |
| Medtronic Inc | 30 | ▲ +88% |
| MicroPort Sorin CRM (Shanghai) Co Ltd | 18 | ▼ -42% |
Wireless transmission, power supply, and digital health are under-served adjacent branches
Against the dominant A61N electrotherapy core, several IPC branches have low patent record counts and low share of the overall landscape, making them worth monitoring as technically adjacent but comparatively sparse areas.
H04B · Wireless Transmission
H04B (Transmission, general) accounts for 38 patent records and approximately 2% of the landscape — sparse relative to the core A61N class. Leadless pacemakers inherently require reliable wireless telemetry for programming and monitoring, and NanoStim Inc’s secondary focus on H04B 13 suggests the technical need is recognized but underfiled. An applicant with wireless communication expertise could develop differentiated IP in device-to-programmer and inter-device communication protocols, provided they can navigate the existing NanoStim and Medtronic records in this branch.
Search this in Eureka →H02J · Power Supply & Energy Harvesting
H02J (Power supply and grid systems) shows only 9 patent records and approximately 1% share, despite energy autonomy being a fundamental constraint in miniaturized implantable devices. Battery longevity and wireless recharging are clinically significant unmet needs. This branch is sparse enough that a focused filing program targeting energy harvesting, wireless power transfer, or ultra-low-power circuit architectures for implantables could establish a defensible adjacent position without immediately colliding with the core A61N incumbents.
Search this in Eureka →Frequently asked questions
The landscape covers 725 patent families. The applicant ranking is based on patent records, which can differ from the family count because a single family may be counted across multiple jurisdictions or IPC branches.
Pacesetter Inc is the top-ranked applicant with 381 patent records, more than double the second-ranked applicant, Biotronik SE & Co KG (167 records). The top five filers together account for 78% of the hundred largest filers’ combined records.
The field is classified as Decline, with annual filing volume easing back from a peak in 2020 (118 patent records). The most recent years (2024–2025) show very low counts, but those figures are subject to significant publication lag and should be treated as undercounts of actual activity.
The United States is the lead jurisdiction with 534 patent records, followed by Europe (EPO) with 277 and WIPO (PCT) with 126. China has 40 records, reflecting a growing but currently smaller presence; Japan and Canada each have modest coverage.
A61N (Electrotherapy and radiation therapy) is overwhelmingly dominant with 1,065 patent records. A61B (Diagnosis and surgery) follows with 286 records, and A61M (Devices for body fluids) has 129. Wireless transmission (H04B), healthcare informatics (G16H), antennas (H01Q), and power supply (H02J) are represented but sparse relative to the core class.
Among the top applicants tracked for momentum, Medtronic Inc shows a recent filing trend of +88% versus its prior three-year period — the strongest upward trajectory in the group. Biotronik SE & Co KG is relatively stable at -5%, while Pacesetter Inc and MicroPort Sorin CRM (Shanghai) Co Ltd have both declined by approximately 44% and 42% respectively in recent periods.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.